MedPath

HUBEI GUANGJI PHARMACEUTICAL CO., LTD.

Ownership
-
Established
1993-05-28
Employees
93
Market Cap
-
Website
https://www.guangjipharm.com
Introduction

The company was founded in 1969 and listed on the Shenzhen Stock Exchange in 1999. It is a state-owned high-tech enterprise with 54 years of experience. It is the only provincial pharmaceutical listed company in Hubei Province. Changjiang Industrial Investment Group is the controlling shareholder of the company. The company mainly produces vitamin B2, B6, B12, sodium isobutyric acid, lactic acid and lactate series products, gluconic acid series products, starch series products, and pharmaceutical preparation products. It is a major global supplier of vitamin B2 products, a high-tech enterprise, an invisible champion in the pillar industry segment of Hubei Province, a small giant specializing in new giants, and the first batch of enterprises to go to the cloud. The company's industry is pharmaceutical manufacturing. It mainly produces vitamin B2, B6 and pharmaceutical products, and is mainly engaged in R&D, production and sales of vitamin raw products. The company's main products are divided into raw material series products and formulation series products. Among them: raw material series products are pharmaceutical grade, food grade, 98% feed grade, 80% feed grade riboflavin and riboflavin sodium phosphate; formulation series products are oral solid preparations and large infusions, isoVC sodium, lactic acid and lactate series products, gluconic acid series products, starch series products, etc. The company's trademark was rated as “Famous Trademark of Hubei Province” and recognized as “China's Famous Trademark” by the State Administration for Industry and Commerce, the feed additive VB2 (riboflavin) product was rated as “Hubei Famous Brand Product”, pharmaceutical-grade riboflavin was rated as “Excellent Enterprise Brand for Exporting Raw Materials in the Chinese Chemical Pharmaceutical Industry”, and the “Kanjiang” brand Vitamin B2 was recognized as a “Huanggang Time-honored Brand”. In 2018, the company received the 9th Pharmaceutical Observer's “2018 Most Commercial Innovative Pharmaceutical Enterprise” certificate, the 20th China International Hi-Tech Fair “Excellent Product Award” certificate, national green factory, national intellectual property advantage enterprise, and selected as a science reform enterprise by the State Council's State-owned Assets Administration Commission.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

42

NMPA:42

Drug Approvals

Febuxostat Tablets

Product Name
非布司他片
Approval Number
国药准字H20249848
Approval Date
Dec 25, 2024
NMPA

Febuxostat Tablets

Product Name
非布司他片
Approval Number
国药准字H20249847
Approval Date
Dec 25, 2024
NMPA

Valacyclovir Hydrochloride Tablets

Product Name
盐酸伐昔洛韦片
Approval Number
国药准字H20247316
Approval Date
Dec 12, 2024
NMPA

Adefovir Dipivoxil Tablets

Product Name
阿德福韦酯片
Approval Number
国药准字H20140111
Approval Date
Apr 22, 2024
NMPA

Valacyclovir Hydrochloride Tablets

Product Name
盐酸伐昔洛韦片
Approval Number
国药准字H20093192
Approval Date
May 22, 2023
NMPA

Simvastatin Tablets

Product Name
辛伐他汀片
Approval Number
国药准字H20093421
Approval Date
May 22, 2023
NMPA

Pantoprazole Sodium Enteric-Coated Tablets

Product Name
泮托拉唑钠肠溶片
Approval Number
国药准字H20093467
Approval Date
May 22, 2023
NMPA

Linezolid and Glucose Injection

Product Name
利奈唑胺葡萄糖注射液
Approval Number
国药准字H20233283
Approval Date
Mar 21, 2023
NMPA

Lafutidine Granules

Product Name
拉呋替丁颗粒
Approval Number
国药准字H20080156
Approval Date
Jul 13, 2022
NMPA

Tinidazole

Approval Number
国药准字H10950092
Approval Date
Apr 25, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.